Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial

Transplantation

Volumn 90, Issue 2, 2010, Pages 175-183

  Guba, Markus ^a   Pratschke, Johann ^b   Hugo, Christian ^c   Krämer, Bernhard K ^d,e   Nohr Westphal, Constanze ^f   Brockmann, Jens ^g   Andrassy, Joachim ^a   Reinke, Petra ^b   Pressmar, Katharina ^c   Hakenberg, Oliver ^f   Fischereder, Michael ^a   Pascher, Andreas ^b   Illner, Wolf Dieter ^a   Banas, Bernhard ^d   Jauch, Karl Walter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF ROSTOCK   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Calcineurin inhibitor free immunosuppression; Kidney transplantation; Randomized clinical trial; Sirolimus

Indexed keywords

CIDOFOVIR; CREATININE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ANEMIA; ARTICLE; CANCER SURGERY; CLINICAL TRIAL; COLON CANCER; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED CANCER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FEMALE; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERLIPIDEMIA; KIDNEY CARCINOMA; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NOSE CAVITY CANCER; OPEN STUDY; PNEUMONIA; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN INFECTION; SQUAMOUS CELL CARCINOMA; SURVIVAL; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VASCULAR DISEASE; VASCULAR HYPERTONIA; WOUND HEALING IMPAIRMENT;

ACNE VULGARIS; ADRENAL CORTEX HORMONES; ADULT; ANTILYMPHOCYTE SERUM; CALCINEURIN; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PATIENT SELECTION; PROSPECTIVE STUDIES; SAFETY; SIROLIMUS; TIME FACTORS; TISSUE DONORS;

EID: 77954952597     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e11798     Document Type: Article

References (24)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of im-provementin renal allograft survival despiteamarked decreaseinacute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
2. Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003; 349: 2288.
3. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation.Transplantation 2002; 73: 1923.
4. Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immuno-suppression\De novo malignancy after renal transplantation: The experience of the Transplantation Center Munich. Kidney Int 2007; 71: 1271.
5. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to cal-cineurin inhibitor drugs. Transplantation 2007; 83: 883.
6. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
7. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
8. Dean PG, Grande JP, SethiS,et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation 2008; 85: 1212.
9. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953.
10. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522.
11. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
12. Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant 2007; 21: 460.
13. Tiong HY, Flechner SM, Zhou L, et al. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients. Transplantation 2009; 87: 296.
14. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
15. Oberbauer R, Kreis H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364.
16. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine tosirolimus 3months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115.
17. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor neph-rotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
18. Moxham VF, Karegli J, Phillips RE, et al. Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection. J Immunol 2008; 180: 3910.
19. Samsel R, Pliszczynski J, Chmura A, et al. Safety and efficacy of high dose ATG bolus administration on rewascularization in kidney graft patients\Long term results. Ann Transplant 2008; 13: 32.
20. Hartmann B, Schmid G, Graeb C, et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: A novel approach for tailored immunosuppressive therapy. Kidney Int 2005; 68: 2593.
21. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomialPneumocystis jirovecii transmission among16patients after kidney transplantation. J Clin Microbiol 2008; 46: 966.
22. Johnson RA, Wang X, Ma XL, et al. Human cytomegalovirus up-regu-lates the phosphatidylinositol 3-kinase (PI3-K) pathway: Inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001; 75: 6022.
23. Wang FZ, Weber F, Croce C, et al. Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J Virol 2008; 82: 9065.
24. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108.